Literature DB >> 25477145

Exact calculation of power and sample size in bioequivalence studies using two one-sided tests.

Meiyu Shen1, Estelle Russek-Cohen, Eric V Slud.   

Abstract

The number of subjects in a pharmacokinetic two-period two-treatment crossover bioequivalence study is typically small, most often less than 60. The most common approach to testing for bioequivalence is the two one-sided tests procedure. No explicit mathematical formula for the power function in the context of the two one-sided tests procedure exists in the statistical literature, although the exact power based on Owen's special case of bivariate noncentral t-distribution has been tabulated and graphed. Several approximations have previously been published for the probability of rejection in the two one-sided tests procedure for crossover bioequivalence studies. These approximations and associated sample size formulas are reviewed in this article and compared for various parameter combinations with exact power formulas derived here, which are computed analytically as univariate integrals and which have been validated by Monte Carlo simulations. The exact formulas for power and sample size are shown to improve markedly in realistic parameter settings over the previous approximations.
Copyright © 2014 John Wiley & Sons, Ltd.

Keywords:  bioequivalence; crossover; pharmacokinetic study; power; sample size; single endpoint

Mesh:

Substances:

Year:  2014        PMID: 25477145     DOI: 10.1002/pst.1666

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  2 in total

1.  A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA(®)) and generic novo-methylphenidate ER-C (NOVO-generic).

Authors:  Angelo Fallu; Farida Dabouz; Melissa Furtado; Leena Anand; Martin A Katzman
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-01

2.  An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment.

Authors:  Kejian Wu; Haitao Pan; Chen Li; Qingbo Zhao; Ling Wang; Jielai Xia
Journal:  PLoS One       Date:  2018-12-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.